by Dr. Joshua Sinai
This bi-weekly “Bio Attack Risk Report” brings politicians, government agency heads, and business executives (including leaders of not-for-profit enterprises) up to date on significant news regarding the risks associated with bio outbreaks at all levels of global society, from enterprises to regions to nations to international (pandemics), and whether nature-made or human-manufactured by terrorists.
Frenit Nirappil, “What to know about the bird flu outbreak as concerns about U.S. cases grow,” Washington Post, December 19, 2024, https://www.washingtonpost.com/health/2024/12/19/bird-flu-outbreak-symptoms-vaccine-explained/
The risks associated with the bird flu outbreak in the United States are escalating in severity after California declared a state of emergency to confront its spread in dairy cows. This followed reporting of the first severe illness caused by the virus in Louisiana. “Bird flu” refers to a collection of influenza A viruses (known as H5N1 strains) that infect wild birds, which forces poultry farmers to cull millions of chickens, and can periodically spark human outbreaks. While public health experts consider bird flu as a low-risk for the general public, there is concern that if left unchecked it will transform to transmit easily between humans. As the Trump Administration takes office in mid-January 2025, the H5N1 strain of avian influenza is one of the top emerging infectious-disease threats facing the United States.
____________________________________________________________________
CDC, CFA: Modeling and Forecasting, Current Epidemic Trends (Based on Rt) for States, https://www.cdc.gov/cfa-modeling-and-forecasting/rt-estimates/index.html
As of December 17, 2024, the CDC estimates that COVID-19 infections are growing or likely growing in 36 states, declining or likely declining in 0 states, and not changing in 11 states. Additionally, as of December 17, 2024, the CDC estimates that influenza infections are growing or likely growing in 46 states, declining or likely declining in 0 states, and not changing in 1 state.
____________________________________________________________________
World Health Organization (WHO), “Number of COVID-19 cases reported to WHO
World, 28 days to 8 December 2024,” https://data.who.int/dashboards/covid19/cases.
For the period 28 days to 8 December 2024, 191,593 COVID-19 cases were reported worldwide, a decrease of 13,545cases compared to the previous 28 days.
____________________________________________________________________
Buckinghamshire Disability Service, “BuDS Covid-19 Update Week Ending 10th November 2024,” https://buds.org.uk/covid-19-risk-assessment-week-ending-10-november-2024/.
While the current Covid-19 wave in England continues to slowly decrease, the risk of meeting an infected person in one’s everyday life remains High. As of 10 November 2024, Covid infection levels in England had fallen to around 1 in every 154 people infected, but BuDS are still predicting a Christmas and New Year infection peak, which has been seen in every year since 2020.
____________________________________________________________________
New York State, Department of Health, “New York State Department of Health Recommends 2024–2025 COVID-19 Vaccination for All New Yorkers Ages 6-Months and Older; CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for the Immunocompromised and Adults 65+,” November 7, 2024, https://www.health.ny.gov/press/releases/2024/2024-11-07_covid-19_vaccination.htm.
The New York State Department of Health recommends all New Yorkers over the age of 6 months receive the new COVID-19 vaccine as respiratory illness season begins. This parallels the Centers for Disease Control and Prevention (CDC) which recently recommended that adults ages 65 and older and those who are moderately or severely immunocompromised should receive a second dose of the 2024-2025 COVID-19 vaccine six months after their first dose.
Dr. Joshua Sinai is a Member of Safely2Prosperity’s Advisory Board. He may be reached for
comment at text: 301-385-8540.
© 2024 Safely2Prosperity LLC. ALL RIGHTS RESERVED.
Comentarios